Pfizer ELREXFIO outperforms standard regimens and meets primary endpoint in Phase 3 study in relapsed or refractory multiple myeloma. Company announcement - FT.com.
Pfizer ELREXFIO outperforms standard regimens and meets primary endpoint in Phase 3 study in relapsed or refractory multiple myeloma. Company announcement - FT.com.
Want to see every report in real time?
Hundreds of sources worldwide, translated into your language, with alerts for what matters to you.
Sign up free Already have an account? Log in